Li, Yan <br/><br/>
Linagliptin inhibits high glucose-induced transdifferentiation of hypertrophic scar-derived fibroblasts to myofibroblasts via IGF/Akt/mTOR signalling pathway.  [electronic resource] 

 -  Experimental dermatology  01 2019 
 - 19-27 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1600-0625 
<br/><br/><label>Standard No.: </label>10.1111/exd.13800  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Actins--metabolism<br/>Adult<br/>Cell Proliferation<br/>Cell Transdifferentiation<br/>Cicatrix, Hypertrophic--drug therapy<br/>Collagen Type I--metabolism<br/>Collagen Type III--metabolism<br/>Fibroblasts--cytology<br/>Glucose<br/>Humans<br/>Insulin-Like Growth Factor I--metabolism<br/>Linagliptin--pharmacology<br/>Muscle, Smooth--metabolism<br/>Myofibroblasts--cytology<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Signal Transduction<br/>TOR Serine-Threonine Kinases--metabolism<br/>Wound Healing<br/>Young Adult